透明细胞肾细胞癌分子亚型对完全转移灶切除术后结局的预后价值
该单中心回顾性研究纳入1995至2017年43例接受完全转移灶切除术且未行系统治疗的转移性透明细胞肾细胞癌患者,用35基因表达分类器判定ccrcc1-4亚型。预后良好型ccrcc2&3的中位无病生存、至系统治疗时间、肿瘤特异生存和总生存均显著优于中/差预后型ccrcc1&4,多因素分析中分类保持独立。
要点
- ccrcc1&4型完全转移灶切除术后中位无病生存仅9个月,ccrcc2&3型为23个月。
- ccrcc1&4型至系统治疗中位28个月,ccrcc2&3型为92个月。
- 分子分型在多因素分析中为独立预后因素,四亚型单独比较仍显著。
核心结论
- 即使经过临床筛选,ccrcc1或ccrcc4型患者完全转移灶切除术后复发风险更高。
- ccrcc2或ccrcc3型患者通常获得较长无病生存。
- 该分型需在更大队列中验证后才能作为预后标志物。
研究设计与样本
- 单中心回顾性研究,1995至2017年纳入43例接受完全转移灶切除术且未行系统治疗的透明细胞肾细胞癌患者。
- 采用已建立的35基因表达分类器判定ccrcc1-4分子亚型。
主要发现
- ccrcc2&3型对比ccrcc1&4型:中位无病生存23个月对9个月,p=0.011,HR=2.6。
- ccrcc2&3型对比ccrcc1&4型:至系统治疗中位时间92个月对28个月,p=0.003,HR=3.3。
- ccrcc2&3型对比ccrcc1&4型:中位肿瘤特异生存133个月对50个月,p<0.001,HR=2.7。
- ccrcc2&3型对比ccrcc1&4型:中位总生存127个月对50个月,p=0.011,HR=2.5。
- 多因素分析中该分类保持独立,四亚型单独比较结局仍显著不同。
临床怎么用
- 对拟行完全转移灶切除术的转移性透明细胞肾细胞癌患者,可考虑分子亚型辅助预判复发风险。
- ccrcc1或ccrcc4型患者术后早期复发风险较高,可能需更密切随访或考虑其他治疗选择。
局限性
- 单中心回顾性研究,样本量43例。
- 表达谱内在异质性是该方法的局限。
- 结果需在更大队列中验证以确立亚型作为预后标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastasectomy is routinely performed in selected patients with metastatic clear-cell renal cell carcinoma (ccRCC) as an alternative to systemic therapy. In the absence of randomized trials, the benefit and best way of patient selection remain unclear. Earlier, we described four molecular ccRCC-subtypes (ccrcc1-4) that have a prognostic and predictive value upon first-line sunitinib or pazopanib. OBJECTIVE: Assess the prognostic value of ccrcc1-4 subtypes after complete metastasectomy. (1) Compare outcomes of good-prognosis ccrccc2&3-tumors with intermediate/poor-prognosis ccrcc1&4-tumors. (2) Compare outcomes of the four subtypes separately. DESIGN, SETTING, AND PARTICIPANTS: Single-center retrospective study (1995-2017), assessing 43 ccRCC patients undergoing complete metastasectomy without systemic treatment. INTERVENTION: Molecular subtype determined with established 35-gene expression classifier. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Median disease-free survival (DFS), time to systemic therapy, cancer-specific (CSS) and overall survival (OS) from metastasectomy, estimated with Kaplan-Meier method and tested against other predictors with multivariable Cox regression. RESULTS AND LIMITATIONS: Median DFS was 23 mo for ccrcc2&3-tumors versus 9 mo for ccrcc1&4-tumors (p=0.011, hazard ratio [HR]=2.6). Median time to systemic therapy was 92 mo versus 28 mo (p=0.003, HR=3.3). Median CSS was 133 mo versus 50 mo (p<0.001, HR=2.7). Median OS was 127 mo versus 50 mo (p=0.011, HR=2.5). The classification remained independent upon multivariable analysis. Outcomes remained significantly different when comparing four subtypes separately. The intrinsic heterogeneity of expression profiles is a limitation of this approach. CONCLUSION: Even after clinical patient selection, patients with a ccrcc1- or ccrcc4-tumor are at a higher risk of relapse after complete metastasectomy. Patients with a ccrcc2- or ccrcc3-tumor usually experience a long DFS. These results need validation in a larger cohort to establish the subtypes as prognostic marker. PATIENT SUMMARY: Metastasectomy is recommended for some patients with metastatic clear-cell kidney cancer; however, we do not know who will benefit the most. We show that molecular subtypes increase the possibility to predict which patients are at risk for early relapse after metastasectomy and who may benefit more from other treatment options.
引用
- Verbiest A, Couchy G, Job S, et al. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. Eur Urol. 2018. PMID: 29463434. doi:10.1016/j.eururo.2018.01.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。